Table A1.

Classification of Chemotherapy Drugs Received by Study Population

Classification	Drugs
Alkylating agents	Busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, procarbazine, streptozocin, temozolomide
Antimetabolites	Azacitidine, capecitabine, cladribine, clofarabine, cytarabine, cytarabine liposome, decitabine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, pemetrexed, pentostatin, thioguanine
Mitotic inhibitors	Docetaxel, ixabepilone, vinblastine, vincristine, vinorelbine
Antitumor antibiotics	Bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin HCl, idarubicin, mitomycin, mitoxantrone
Immunotherapy	Aldesleukin, alemtuzumab, bevacizumab, cetuximab, gemtuzumab ozogamicin, interferon alfa-2b, rituximab
Hormone therapy	Anastrozole, bicalutamide, estramustine phosphate, exemestane, flutamide, fulvestrant, goserelin, letrozole, leuprolide, megestrol, mitotane, nilutamide, tamoxifen
Targeted therapy	Bortezomib, dasatinib, erlotinib, everolimus, imatinib, lapatinib, sorafenib, sunitinib, temsirolimus, vorinostat
Topoisomerase inhibitors	Etoposide, irinotecan, topotecan
Miscellaneous chemotherapy drugs	Asparaginase, denileukin diftitox, pegaspargase, porfimer
Differentiating agents	Arsenic trioxide, bexarotene, tretinoin